摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

8-chloro-1-methyl-6-phenyl-4H,6H-benzo[b]imidazo[1,5-d][1,4]diazepin-5-one | 67045-89-0

中文名称
——
中文别名
——
英文名称
8-chloro-1-methyl-6-phenyl-4H,6H-benzo[b]imidazo[1,5-d][1,4]diazepin-5-one
英文别名
8-Chloro-4,6-dihydro-1-methyl-6-phenyl-5H-imidazo[1,5-a][1,5]benzodiazepin-5-one;8-chloro-1-methyl-6-phenyl-4H-imidazo[1,5-a][1,5]benzodiazepin-5-one
8-chloro-1-methyl-6-phenyl-4<i>H</i>,6<i>H</i>-benzo[<i>b</i>]imidazo[1,5-<i>d</i>][1,4]diazepin-5-one化学式
CAS
67045-89-0
化学式
C18H14ClN3O
mdl
——
分子量
323.782
InChiKey
IIMBZVUDKMDPET-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    23
  • 可旋转键数:
    1
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.11
  • 拓扑面积:
    38.1
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为产物:
    描述:
    7-Chloro-5-phenyl-1,2,3,4-tetrahydro-2-nitromethylene-5H-1,5-benzodiazepin-4-one 在 aluminum nickel 二氧化锰 作用下, 以 N-甲基乙酰胺5,5-dimethyl-1,3-cyclohexadiene乙醇甲苯 为溶剂, 生成 8-chloro-1-methyl-6-phenyl-4H,6H-benzo[b]imidazo[1,5-d][1,4]diazepin-5-one
    参考文献:
    名称:
    Imidazo [1,5-a][1,5] benzodiazepines
    摘要:
    本发明涉及以下结构的化合物:##STR1## 其中X是氢或卤素;R.sub.1是氢、卤素或三氟甲基;R.sub.2是氢或较低的烷基;R.sub.3是氢、--COO较低烷基或CON(R.sub.4).sub.2,其中R.sub.4是较低烷基或氢,可能不同,并且其药学上可接受的盐。还提供了制备这些化合物的方法,以及包含本发明活性化合物的药物配方。上述结构的化合物可用作抗焦虑药、抗惊厥药、肌肉松弛剂和镇静剂。
    公开号:
    US04080323A1
点击查看最新优质反应信息

文献信息

  • 1,2,3,5-Tetrahydro-4H-1,5-benzodiazepine-4-ones
    申请人:Hoffmann-La Roche Inc.
    公开号:US04111931A1
    公开(公告)日:1978-09-05
    The present invention concerns compounds of the formula ##STR1## wherein X is hydrogen or halogen; R.sub.1 is hydrogen, halogen or trifluoromethyl; R.sub.2 is hydrogen or lower alkyl; and R.sub.3 is hydrogen, --COO lower alkyl or CON(R.sub.4).sub.2 wherein R.sub.2 is lower alkyl or hydrogen and may be different and the pharmaceutically acceptable salts thereof. Also provided are methods for the preparation of these compounds as well as pharmaceutical formulations which contain the active compounds of this invention. The compounds of the formula illustrated above are useful as anxiolytics, anticonvulsants, muscle relaxants and sedative agents.
    本发明涉及公式为##STR1##的化合物,其中X为氢或卤素; R.sub.1为氢,卤素或三甲基; R.sub.2为氢或较低的烷基; R.sub.3为氢,--COO较低的烷基或CON(R.sub.4).sub.2,其中R.sub.2是较低的烷基或氢,可能不同,并且其药学上可接受的盐。还提供了制备这些化合物的方法以及包含本发明活性化合物的制药配方。上述公式的化合物可用作抗焦虑剂,抗惊厥剂,肌肉松弛剂和镇静剂。
  • Process for preparing imidazo[1,5-A][1,5]benzodiazepines
    申请人:Hoffmann-La Roche Inc.
    公开号:US04137229A1
    公开(公告)日:1979-01-30
    The present invention concerns compounds of the formula ##STR1## wherein X is hydrogen or halogen; R.sub.1 is hydrogen, halogen or trifluoromethyl; R.sub.2 is hydrogen or lower alkyl; and R.sub.3 is hydrogen, --COO lower alkyl or CON(R.sub.4).sub.2 wherein R.sub.4 is lower alkyl or hydrogen and may be different and the pharmaceutically acceptable salts thereof. Also provided are methods for the preparation of these compounds as well as pharmaceutical formulations which contain the active compounds of this invention. The compounds of the formula illustrated above are useful as anxiolytics, anticonvulsants, muscle relaxants and sedative agents.
    本发明涉及公式 ##STR1## 的化合物,其中X为氢或卤素;R.sub.1为氢、卤素或三甲基;R.sub.2为氢或较低的烷基;R.sub.3为氢、--COO较低的烷基或CON(R.sub.4).sub.2,其中R.sub.4为较低的烷基或氢且可能不同,以及它们的药学上可接受的盐。本发明还提供了制备这些化合物的方法以及包含本发明活性化合物的药物制剂。上述公式的化合物可用作抗焦虑剂、抗癫痫药、肌肉松弛剂和镇静剂。
  • US4080323A
    申请人:——
    公开号:US4080323A
    公开(公告)日:1978-03-21
  • US4137229A
    申请人:——
    公开号:US4137229A
    公开(公告)日:1979-01-30
  • US4111931A
    申请人:——
    公开号:US4111931A
    公开(公告)日:1978-09-05
查看更多

同类化合物

阿斯普尼辛B 阿斯普尼辛 D 阿斯普尼辛 苯佐莫文 新骏河毒素 乙酰胺,N-(4-硝基-2-吡啶基)-,氧化(9CI) TAK960抑制剂 PLK1抑制剂(RO3280) 8H-嘧啶并[4,5-b][1,4]二氮杂卓 8-甲基-5,9-二氢-6H-嘧啶并[4,5-b][1,4]重氮基庚英-6-酮 6H-嘧啶并[4,5-b][1,4]二氮杂卓 4-甲基-6,11-二氢-3H-嘧啶并[4,5-b][1,5]苯并二氮杂卓-2,5-二酮 2-氯-7,7-二氟-5-甲基-5,7,8,9-四氢-6H-嘧啶基[4,5-B][1,4]二氮杂-6-酮 2-氯-5-甲基-5,7,8,9-四氢-6H-嘧啶[4,5-B][1,4]二氮杂6-酮 1H-嘧啶并[4,5-b][1,4]二氮杂卓 5-(2-piperidin-1-yl-ethyl)-5,11-dihydro-benzo[e]pyrido[3,2-b][1,4]diazepin-6-one 4-oxo-2-pyridin-4-yl-5,6,8,9-tetrahydro-4H-1,4a,7-triaza-benzocycloheptene-7-carboxylic acid ethyl ester 7-chloro-5-phenyl-1-propyl-1,3-dihydro-pyrido[3,2-e][1,4]diazepin-2-one 6-methoxy-8-methyl-4-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)pteridin-7(8H)-one 4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-N-((1S,2R)-2-hydroxycyclohexyl)-3-methoxybenzamide 8-chloro-1,2,3,4-tetrahydro-pyrazino[2,1-b]quinazolin-6-one hydrochloride salt of 3-(2-chlorophenyl)-7-[(1-hydroxymethylcyclohexyl)amino]-1-methyl-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1 H)-one {2-[4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido-[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-benzoylamino]-ethyl}-carbamic acid tert-butyl ester (7R)-8-cyclohexyl-2-[(4-fluoro-1H-indazol-5-yl)amino]-5-(3-fluorophenyl)-7-methyl-7,8-dihydropteridin-6(5H)-one 7-ethoxy-8-ethyl-9-methyl-1(3),7-dihydro-[1,3]diazepino[2,1-i]purin-10-one 3-(((1H-indol-3-yl)methylene)amino)-3,4-dihydroquinazolin-2(1H)-one 3-[[(7R)-7-benzyl-2,5,8,11,14-pentazatricyclo[8.4.0.02,6]tetradeca-1(14),3,5,10,12-pentaen-8-yl]sulfonyl]benzoic acid 5-(hydroxyamino)-11H-pyrimido[4,5-b][1,5]benzodiazepine 3-ethyl-7-(3-piperidin-1-yl-propyl)-7,12-dihydro-3H-benzo[b]pyrazolo[4',3':5,6]pyrido[4,3-e][1,4]diazepin-6-one (7R)-7-benzyl-8-[2-(trifluoromethoxy)phenyl]sulfonyl-2,5,8,12,14-pentazatricyclo[8.4.0.02,6]tetradeca-1(14),3,5,10,12-pentaene 3-(9-ethylamino-6-oxo-2,3,3a,4-tetrahydro-1H,6H-5,8,10,10b-tetraazabenzo[e]azulen-5-yl)benzoic acid-N'-acetyl hydrazide 7-chloro-2-oxo-5-phenyl-2,3-dihydro-pyrido[3,2-e][1,4]diazepine-1-carboxylic acid allylamide 6-(4-bromobenzylidene)-6,11-dihydro-13H-isoquinolino[3,2-b]quinazolin-13-one (+/-)-9-methylamino-4-oxo-2-pyridin-4-yl-5,6,8,9-tetrahydro-4H-1,4a,7-triaza-benzocycloheptene-7-carboxylic acid ethyl ester 5-benzyl-2-(1H-indol-4-yl)-6a,7,9,10-tetrahydro-[1,4]oxazino[3,4-h]pteridin-6(5H)-one 4-{[7-(cyclopropylmethoxy)-5-methyl-6-oxo-8-(3-thienyl)-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl]amino}-3-methyl-N-(1-methylpiperidin-4-yl)benzamide 6-(4-chlorobenzylidene)-6,11-dihydro-13H-isoquinolino[3,2-b]quinazolin-13-one 6-benzylidene-6,11-dihydro-13H-isoquinolino[3,2-b]quinazolin-13-one 6-(4-methoxybenzylidene)-6,11-dihydro-13H-isoquinolino[3,2-b]quinazolin-13-one 6-{[(4-dimethylamino)phenyl]methylidene}-6,11-dihydro-13H-isoquino[3,2-b]quinazolin-13-one 1H-spiro[pyrimido[4,5-b]quinoline-5,5'-pyrrolo[2,3-d]pyrimidine]-2,2',4,4',6'(1'H,3H,3'H,7'H,10H)-pentaone tert-butyl 3-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzamido) azetidine-1-carboxylate 4-deoxy-4-amino-7,10-methano-5-deazapteroic acid (S)-N,N-dimethyl 2-[3-(9-ethylamino-6-oxo-2,3,3a,4-tetrahydro-1H,6H-5,8,10,10b-tetraazabenzo[e]azulen-5-yl)phenyl]-1,3-oxazole-4-carboxamide diethyl (4-{[4-{[7-(hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)-2-methyl-3-oxo-2,3-dihydro-1H-isoindol-4-yl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}benzyl)phosphonate 3-[2-(3-methyl-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-quinazolin-4-yl]-4-(6H-thieno[2,3-b]pyrrol-4-yl)-pyrrole-2,5-dione 4-((R)-9-cyclopentyl-7-fluoro-5-methyl-6-oxo-7-vinyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-N-((R)-piperidin-3-yl)benzamide (S)-N,N-dimethyl 5-[3-(9-methylamino-6-oxo-2,3,3a,4-tetrahydro-1H,6H-5,8,10,10b-tetraazabenzo[e]azulenyl)phenyl]-1,3,4-oxadiazole-2-carboxamide 4-[(6-cyclopentyl-2,5-dimethyl-3-oxo-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-9-yl)amino]-3-methoxy-N-(1-methyl-4-piperidyl)benzamide